

## IDL Diagnostics - Still under the radar

Redeye reviews the case for IDL Diagnostics, and while we down our medium-term sales forecasts, we reconsider our long-term estimates. We lengthen our DCF period ending in 2035e (from 2032e) and assume higher market penetrations for its key products.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[IDL Diagnostics - Still under the radar](#)